Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2008

Study Completion Date

August 31, 2009

Conditions
Osteoporosis
Interventions
DRUG

Alendronate

Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Medical University of South Carolina

OTHER

NCT00259857 - Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis | Biotech Hunter | Biotech Hunter